Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

AAV Full/Empty Capsid Ratio by Analytical Ultracentrifugation (AUC)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

AAV Full/Empty Capsid Ratio by Analytical Ultracentrifugation (AUC)

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence in AAV Product Characterization.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Executive Summary

Analytical Ultracentrifugation (AUC) is a first-principles analytical method for determining the full-to-empty capsid ratio of Adeno-Associated Virus (AAV) vector preparations. This ratio is a key quality attribute (CQA) scrutinized by the FDA during IND review. Inaccurate quantification can lead to inconsistent dosing in IND-enabling toxicology studies, increased immunogenicity risk, and potential clinical holds. This analysis provides definitive, high-resolution data on product purity and homogeneity, directly supporting robust CMC packages for next-generation therapeutics.

Frequently Asked Questions

Why is the AAV full/empty capsid ratio a focus for regulatory agencies?

The ratio is a direct measure of product consistency and purity. Empty capsids contribute to the total viral particle dose without delivering a therapeutic payload, which can unnecessarily increase the immunogenic load on a patient. Regulatory bodies require precise characterization to ensure dose accuracy and to minimize potential adverse immune responses, as an excess of empty capsids can impact the safety profile of an AAV therapeutic.

What makes Analytical Ultracentrifugation (AUC) a preferred method for this analysis?

AUC is a matrix-free, solution-based technique that separates particles based on their sedimentation velocity, which is directly related to their mass and shape. This allows for highly accurate and resolved quantification of full (genome-containing) and empty capsids without the potential artifacts from column interactions seen in chromatographic methods. It is considered a gold-standard orthogonal method for validating AAV purity.

How does accurate capsid analysis support an 18-24 month IND timeline?

Integrating a definitive analytical method like AUC early in process development prevents costly delays. It provides a robust data package that minimizes regulatory questions about product characterization, a common bottleneck in CMC development. This analytical certainty accelerates the path through preclinical development and into a successful IND submission.

Defining AAV Product Purity for IND Submission

The precise characterization of an AAV vector is foundational to any successful IND-enabling program. Among the most important CQAs is the ratio of genome-containing “full” capsids to “empty” capsids. An excess of empty capsids presents a significant challenge, as these non-functional particles can still trigger host immune responses without contributing to therapeutic efficacy (PMID: 28323492).

Analytical Ultracentrifugation provides a definitive measurement of this ratio. By subjecting the AAV preparation to high centrifugal forces, AUC separates particles based on their fundamental hydrodynamic properties. Full capsids, containing the dense genetic payload, sediment faster than their empty counterparts, allowing for direct and precise quantification of each species in the sample.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

The Role of AUC in De-risking AAV Programs

Relying on less direct or lower-resolution methods for capsid analysis can introduce uncertainty into a development program. This uncertainty has downstream consequences, impacting the interpretation of dose-response data from nonclinical toxicology studies and complicating the establishment of a safe clinical starting dose.

  • Dose Accuracy: Inaccurate full/empty ratios lead to inconsistent dosing of the active component in pivotal GxP toxicology studies.

  • Immunogenicity Profile: A well-characterized product with a high full-to-empty ratio minimizes the administration of non-functional viral proteins, which is a key consideration for the overall safety profile.

  • CMC Robustness: The FDA expects a robust, phase-appropriate analytical control strategy. Employing AUC demonstrates a commitment to rigorous product understanding and control.

For novel or engineered capsids designed for specific tissue targeting, such as those intended to cross the blood-brain barrier, precise biophysical characterization is even more important. The unique properties of these vectors demand analytical methods that can confirm product identity and purity without ambiguity (PMID: 37199615).

Franklin Biolabs’ Analytical Approach

Our approach to AAV analytics is built on decades of scientific leadership in the field. The core scientific team responsible for our services established a track record that includes a 100% successful IND rate since 2019, a history that predates the formal launch of Franklin Biolabs in 2024. This deep experience informs our analytical strategies, ensuring that the data generated for your program is built for regulatory acceptance. As one biotech partner noted, our team has “Vast knowledge in all aspects of vector production and analytics.”

We integrate advanced analytical methods like AUC as part of a comprehensive characterization package. This strategy provides the clear, unambiguous data required to accelerate development timelines. To learn more about our integrated approach to vector manufacturing and analytics, view our discussion on success factors for AAV programs.

Our work is performed within a >100,000 sq ft facility designed to support integrated preclinical, bioanalytical, and CMC programs. This infrastructure, combined with our scientific expertise, provides a clear path to IND.

Return to the main services overview: Vector | CMC | Analytics Services.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities